Targeted Protein Degradation for Treatment of Hematologic Malignancies Addressing Both the Enzymatic and Scaffolding Functions of BTK Using NX-5948 and NX-2127 in the Clinic
Wednesday, July 26, 2023 BiopharmaWatch Research 1 min read
Key Takeaway: Nurix is advancing its multi-modal portfolio aimed at treating hematologic malignancies through targeted protein degradation. The company is focusing on the dual functions of BTK, utilizing NX-5948 and NX-2127 in clinical settings. This approach aims to provide innovative therapies for cancer and autoimmune diseases.
Price reaction · baseline $9.56 (2023-07-25 close) · hit after-hours · clean, no other NRIX news in the window
day 0 close · peak
-1.6%
Market Sentiment Analysis
POSITIVE FACTORS
Focus on novel scientific insights for breakthrough therapies.
Advancement of a multi-modal portfolio targeting cancer and autoimmune diseases.
Commitment to addressing both enzymatic and scaffolding functions of BTK.
BiopharmaWatch Analysis
From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+85%
120-day peak, hindsight
Typical move
4.4%
average across 9 past catalysts
Cash runway
~14 mo
Low dilution risk
Lead asset
NX-5948
Phase 3 · B-cell Lymphoma
Full Press Release Details
RESOURCE LIBRARY
RESOURCE LIBRARY
At Nurix, we are dedicated to translating novel scientific insights into breakthrough therapies, advancing our multi-modal portfolio of wholly owned and partnered assets to outmatch cancer and autoimmune disease. Access our protein degradation resources below.
Filter by
Frequently Asked Questions
What is Nurix focusing on in their research?
Nurix is dedicated to advancing therapies for cancer and autoimmune diseases.
What are NX-5948 and NX-2127 used for?
They are used in clinical settings to target both enzymatic and scaffolding functions of BTK.
What type of diseases does Nurix aim to treat?
Nurix aims to treat hematologic malignancies and autoimmune diseases.